基本氨基酸三,氨酸,氨酸和乳腺癌化疗之间的相关性
Yafeng Lv1, Xuan Yang1, Ying Song1
1Department of Breast Surgery, the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
Technology in cancer research & treatment
|October 22, 2024
概括
乳腺癌患者的血清氨酸和氨酸水平有显著差异,这表明它们作为诊断生物标志物的潜力. 化疗方案在研究中没有实质性地改变这些氨基酸水平.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 临床诊断 临床诊断 临床诊断
背景情况:
- 氨基酸在细胞代谢中起着至关重要的作用,并与包括癌症在内的各种疾病有关.
- 特定氨基酸特征的变化可以作为疾病状态和治疗反应的指标.
- 了解乳腺癌中的血清氨基酸变异对于改善诊断和治疗策略至关重要.
研究的目的:
- 为了研究乳腺癌患者的酸,氨酸和氨酸的血清水平.
- 探索这些氨基酸和化疗方案之间的相关性.
- 评估它们在临床诊断和乳腺癌治疗中的重要性.
主要方法:
- 在云南癌症医院收集了216例 (91例健康,38例良性瘤,87例癌症) 的临床数据.
- 使用液体染色学-并联质谱法测量血清氨基酸水平.
- 使用统计分析 (克鲁斯卡尔-瓦利斯H测试,威尔科克森测试,χ2测试,费舍尔精确测试) 来比较群体并评估相关性.
主要成果:
- 在健康,良性瘤和乳腺癌群体 (P < .001) 中观察到血清氨酸和氨酸水平的显著差异.
- 托水平在各组之间没有显示统计学上显著的差异.
- 没有发现传统化疗方案对lysine和phenylalanine水平有重大影响.
结论:
- 血清氨酸和氨酸可以作为乳腺癌检测的潜在生物标志物.
- 选择化疗方案似乎不太可能导致这些特定氨基酸水平的显著变化.
- 需要进一步的研究来验证这些发现并探索它们的临床实用性.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
149
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
149
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
227
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
227
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
175
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
175


